Skip to main content

Table 1 Comparison of demographic data between the 2 groups. Numbers indicate median (25th-75th interquartile range)

From: The use of cell salvage during second-stage reimplantation for the treatment of chronic hip periprosthetic joint infection: a retrospective cohort study

Variables Cell salvage reinfused group Control group P-Value
(n = 61) (n = 64)
Gender, male n (%) 32 (52.5) 48 (75.0) 0.221b
Age at reimplantation (year) 59.0 (49.5–70.0) 56.0 (45.3–69.0) 0.527a
BMI (kg/m2) 24.7 (21.9–26.5) 24.1 (22.0–27.5) 0.947a
ASA classification, n (%)    0.568b
 I–II 39 (63.9) 45 (70.3)  
 III 22 (36.1) 19 (29.7)  
Charlson comorbidity index, n (%)    0.342b
 1–2 16 (26.2) 22 (34.4)  
 3–5 27 (44.3) 30 (46.9)  
 ≥ 6 18 (29.5) 12 (18.8)  
Comorbidities, n (%)
 Diabetes mellitus 7 (11.5) 10 (15.6) 0.605b
 Inflammatory arthritis 4 (6.6) 6 (9.4) 0.744b
 Chronic hepatitis 3 (4.9) 5 (7.8) 0.718b
 Chronic anemia 8 (13.1) 11 (9.4) 0.622b
Tobacco use, n (%) 19 (31.1) 28 (43.8) 0.196b
Alcoholism, n (%) 21 (34.4) 25 (39.1) 0.711b
Resistant strain, n (%) 6 (9.8) 6 (9.4) 1.000b
Positive culture, n (%) 16 (26.2) 19 (29.7) 0.695b
McPherson host type, n (%)    0.865b
 A 24 (39.3) 27 (42.2)  
 B 25 (41.0) 27 (42.2)  
 C 12 (19.7) 10 (15.6)  
Components revised, n (%)    0.380b
 Acetabular component 4 (6.6) 2 (3.1)  
 Femoral component 0 (0.0) 2 (3.1)  
 Dual components 57 (93.4) 60 (93.8)  
Time of antibiotic administration (week)
Spacer stage duration (mo) 6.0 (4.5–11.0) 7.0 (5.0–11.8) 0.630a
Follow-up (mo) 70.0 (54.5–94.0) 75.0 (46.3–84.8) 0.592a
Failure after reimplantation, n (%) 1 (1.6) 3 (4.7) 0.330c
  1. ASA American Society of Anesthesiologists, BMI body mass index
  2. aThe Mann–Whitney U test
  3. bThe Fisher exact test
  4. cThe log-rank test